JP2008526749A - 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達 - Google Patents

自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達 Download PDF

Info

Publication number
JP2008526749A
JP2008526749A JP2007549507A JP2007549507A JP2008526749A JP 2008526749 A JP2008526749 A JP 2008526749A JP 2007549507 A JP2007549507 A JP 2007549507A JP 2007549507 A JP2007549507 A JP 2007549507A JP 2008526749 A JP2008526749 A JP 2008526749A
Authority
JP
Japan
Prior art keywords
peptide
pdgf
self
membrane
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007549507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526749A5 (https=
Inventor
リチャード ティー． リー，
パトリック シエ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2008526749A publication Critical patent/JP2008526749A/ja
Publication of JP2008526749A5 publication Critical patent/JP2008526749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2007549507A 2005-01-04 2005-12-29 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達 Pending JP2008526749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64099805P 2005-01-04 2005-01-04
US70231805P 2005-07-26 2005-07-26
PCT/US2005/046768 WO2006073889A2 (en) 2005-01-04 2005-12-29 Sustained delivery of pdgf using self-assembling peptide nanofibers

Publications (2)

Publication Number Publication Date
JP2008526749A true JP2008526749A (ja) 2008-07-24
JP2008526749A5 JP2008526749A5 (https=) 2009-01-22

Family

ID=36648006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549507A Pending JP2008526749A (ja) 2005-01-04 2005-12-29 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達

Country Status (6)

Country Link
US (1) US7429567B2 (https=)
EP (1) EP1833504A4 (https=)
JP (1) JP2008526749A (https=)
AU (1) AU2005323062A1 (https=)
CA (1) CA2592292A1 (https=)
WO (1) WO2006073889A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532845A (ja) * 2012-09-21 2015-11-16 テクノロヒアス アバンサダス インスピラリア ス．ル．Ｔｅｃｎｏｌｏｇｉａｓ Ａｖａｎｚａｄａｓ Ｉｎｓｐｉｒａｌｉａ Ｓ．Ｌ．（２５） 心臓修復パッチの新しいスキャフォールド
WO2020171161A1 (ja) * 2019-02-20 2020-08-27 国立大学法人東京農工大学 自己組織化ペプチド

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5255274B2 (ja) * 2004-07-06 2013-08-07 スリーディー マトリックス， インコーポレイテッド 精製両親媒性ペプチド組成物およびその使用
DK1879606T3 (da) * 2005-04-25 2013-09-23 Massachusetts Inst Technology Selvorganiserende peptider til fremme af hæmostase
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
ES2673947T3 (es) * 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
WO2008039483A2 (en) * 2006-09-26 2008-04-03 Massachusetts Institute Of Technology Modified self-assembling peptides
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
WO2008073392A2 (en) * 2006-12-11 2008-06-19 3D Matrix, Inc. Compositions and methods for cardiac tissue protection and regeneration
US9415084B2 (en) * 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
RU2011118341A (ru) 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
JP5732691B2 (ja) * 2010-01-14 2015-06-10 学校法人同志社 インスリン製剤
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
WO2014004467A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
WO2014008400A2 (en) 2012-07-06 2014-01-09 3-D Matrix, Inc. Fill-finish process for peptide solutions
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
ES2756531T3 (es) 2013-08-22 2020-04-27 Arch Biosurgery Inc Mallas implantables para controlar el movimiento de fluidos
EP2853256A1 (en) 2013-09-25 2015-04-01 Credentis AG Dental care product for tooth whitening
EP3049054B1 (en) 2013-09-25 2018-04-04 Credentis AG Dental care product for tooth whitening
BR112016019510A2 (pt) 2014-03-10 2017-10-24 3 D Matrix Ltd esterilização e filtração de composições de peptídeos
US10245299B2 (en) 2014-03-10 2019-04-02 3-D Matrix, Ltd. Autoassembling peptides for the treatment of pulmonary bulla
RU2016139369A (ru) 2014-03-10 2018-04-10 3-Д Матрикс, Лтд. Композиции самоорганизующихся пептидов
CN104497107B (zh) * 2014-12-08 2017-09-19 重庆医科大学 一种自组装短肽及其在细胞三维培养中的应用
CN104693277B (zh) * 2015-03-26 2018-02-13 罗忠礼 一种自组装短肽及其在细胞三维培养中的应用
CN105148289B (zh) * 2015-09-30 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
CN105288653B (zh) * 2015-11-19 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3248591A1 (en) 2016-05-24 2017-11-29 Credentis AG Method and product for caries treatment
EP3248590A1 (en) 2016-05-24 2017-11-29 Credentis AG Personal dental care product for caries treatment
JP2021506815A (ja) 2017-12-15 2021-02-22 株式会社スリー・ディー・マトリックス 界面活性ペプチドナノ構造および薬物送達における使用
EP3831360A1 (en) 2019-12-04 2021-06-09 Credentis AG Personal dental care product for preventing demineralisation
US11154470B1 (en) 2020-07-31 2021-10-26 vVardis AG Anti-inflammatory and senolytic dental care product with tooth whitening characteristics
CN114181295B (zh) * 2021-12-15 2023-07-04 湖南大学 一种多肽衍生物及其用途、水凝胶及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003096972A2 (en) * 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
WO2004091592A2 (en) * 2003-04-15 2004-10-28 Guidant Corporation, V.I. Methods and compositions to treat myocardial conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
EP0697883A1 (en) * 1993-04-29 1996-02-28 Washington University Use of platelet-derived growth factor to improve collateral circulation
EP0832269A1 (en) * 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO2001035932A2 (en) * 1999-11-18 2001-05-25 The Regents Of The University Of Michigan Sustained drug delivery from structural matrices
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
DE60230593D1 (de) * 2001-02-06 2009-02-12 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
EP1379197A4 (en) * 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
KR20030043780A (ko) * 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
US20030139333A1 (en) * 2002-01-18 2003-07-24 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis
AU2003274900A1 (en) * 2002-07-15 2004-02-02 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
AU2003297282A1 (en) * 2002-11-14 2004-06-15 Cornell Research Foundation, Inc. Protection of cardiac myocardium
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP2711025A3 (en) * 2003-06-25 2014-09-10 Massachusetts Institute of Technology Self-assembling peptides incorporating modifications and methods of use thereof
JP5255274B2 (ja) * 2004-07-06 2013-08-07 スリーディー マトリックス， インコーポレイテッド 精製両親媒性ペプチド組成物およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003096972A2 (en) * 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
WO2004091592A2 (en) * 2003-04-15 2004-10-28 Guidant Corporation, V.I. Methods and compositions to treat myocardial conditions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532845A (ja) * 2012-09-21 2015-11-16 テクノロヒアス アバンサダス インスピラリア ス．ル．Ｔｅｃｎｏｌｏｇｉａｓ Ａｖａｎｚａｄａｓ Ｉｎｓｐｉｒａｌｉａ Ｓ．Ｌ．（２５） 心臓修復パッチの新しいスキャフォールド
WO2020171161A1 (ja) * 2019-02-20 2020-08-27 国立大学法人東京農工大学 自己組織化ペプチド
JPWO2020171161A1 (https=) * 2019-02-20 2020-08-27
JP7466876B2 (ja) 2019-02-20 2024-04-15 国立大学法人東京農工大学 自己組織化ペプチド

Also Published As

Publication number Publication date
US7429567B2 (en) 2008-09-30
EP1833504A2 (en) 2007-09-19
EP1833504A4 (en) 2009-08-12
CA2592292A1 (en) 2006-07-13
AU2005323062A1 (en) 2006-07-13
WO2006073889A2 (en) 2006-07-13
WO2006073889A3 (en) 2007-06-14
US20060148703A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
JP2008526749A (ja) 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
Wu et al. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques
Liu et al. A self-assembling peptide hydrogel-based drug co-delivery platform to improve tissue repair after ischemia-reperfusion injury
Yang et al. Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy
JP2018507865A (ja) 肝細胞へのミトコンドリアの標的化移植
US10925852B2 (en) Talc-bound compositions and uses thereof
Nguyen et al. Local release of NECA (5′-(N-ethylcarboxamido) adenosine) from implantable polymeric sheets for enhanced islet revascularization in extrahepatic transplantation site
US20190216956A1 (en) Compositions for radiotherapy and uses thereof
Wu et al. Pretreatment with B-type natriuretic peptide protects the heart from ischemia-reperfusion injury by inhibiting myocardial apoptosis
AU2026201537A1 (en) Alginate-based microcapsulation for the delivery of alpha-CGRP in cardiovascular diseases
US20190015348A1 (en) Composition for inhibiting angiogenesis comprising nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
JP7636812B2 (ja) 創傷治癒を促進するための組成物および方法
WO2018022929A1 (en) Gel-bound compositions for radiotherapy and uses thereof
EP3996733A1 (en) A peptoid-peptide hybrid, nmeg-acgrp, and its use in cardiovascular diseases
RU2824501C2 (ru) Лечение сердечной недостаточности
EP4335433A1 (en) Oral pharmaceutical composition containing teriparatide for prevention or treatment of osteoporosis and preparation method therefor
KR20250037567A (ko) 말초 혈관 질환을 치료하기 위한 조성물 및 방법
JP2017165745A (ja) 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用
US20240190915A1 (en) Peptides for the treatment of cancer
CN120983639A (zh) 一种基于多肽修饰的寡核苷酸纳米递送体系及其应用
US20210236668A1 (en) Compositions for radiotherapy and uses thereof
ES2667814T3 (es) Composiciones farmacéuticas para la cardioprotección
TW202222333A (zh) 治療缺血性疾病之組成物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120213